Research from Atrium Research, Atrium Research Corporation

Atrium Research

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Sentiment for cannabis stocks remains at all time lows with the MSOS and MJ ETFs down 95% and 93% respectively from their highs.</li>
<li>We believe there are solid names in the sector that have formidable growth and expanding margins albeit the tough pricing environment.</li>
<li>The sector trades at historically low multiples, with the Canadian LPs at 7.3x 2025E EBITDA and MSOs at 6.5x.</li>
</ul>


Sentiment for cannabis stocks remains at all time lows with the MSOS and MJ ETFs down 95% and 93% respectively from their highs.
We believe there are solid names in the sector that have formidable growth and expanding margins albeit the tough pricing environment.
The sector trades at historically low multiples, with the Canadian LPs at 7.3x 2025E EBITDA and MSOs at 6.5x.


Glass House Brands Inc - Taking Another Look at Cannabis Stocks

Canada

Cannara Biotech Inc. provides biomedical products. The Company offers organic cannabis for medical purposes. Cannara Biotech serves customers in Canada.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00